Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258594 · ClinicalTrials.gov registry record · NA
Promoting Respect and Ongoing Safety Through Patient-centeredness, Engagement, Communication and Technology
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 4,368
- Enrollment target
NCT02258594 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4,368 participants.
The verdict
NCT02258594, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,368 participants
- Enrollment target
Study Summary
The purpose of this project is to refine, implement, and evaluate a multi-component intervention that achieves sustainable and meaningful impact on healthcare quality, safety, and costs while ensuring dignity and respect for adult oncology and intensive care patients and their care partners. The PROSPECT (Promoting Respect and Ongoing Safety through Patient-centeredness, Engagement, Communication, and Technology) framework will achieve this by enhancing the patient-provider relationship and introducing patient-centered approaches to multi-disciplinary communication and patient education. The PROSPECT framework is based upon a validated structured, team-work training model and novel web-based technology. The overarching goals of this project are to achieve the following: 1. Optimize the overall experience of patients (including their family/care partners) by promoting dignity/respect, encouraging engagement, improving care plan concordance, and enhancing satisfaction. 2. Minimize preventable harms in two environments: intensive care and acute care oncology units. 3. Reduce unnecessary healthcare resource utilization and associated costs.
Interventions
- OTHER Web-Based Patient Centered Toolkit (PCTK)
- BEHAVIORAL The Patient-SatisfActive® Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,368 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258594
The ClinicalTrials.gov registry entry for NCT02258594 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4,368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Web-Based Patient Centered Toolkit (PCTK) is the first listed.
NCT02258594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258594 about?
NCT02258594 is a clinical study titled "Promoting Respect and Ongoing Safety Through Patient-centeredness, Engagement, Communication and Technology". The purpose of this project is to refine, implement, and evaluate a multi-component intervention that achieves sustainable and meaningful impact on healthcare quality, safety, and costs while ensuring dignity and respect for adult oncology and intensive care patients and their care partners. The PRO...
What is the current status of trial NCT02258594?
This trial is currently completed. It is a NA study. The enrollment target is 4,368 participants. The study started on 2013-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02258594?
The interventions under investigation include: Web-Based Patient Centered Toolkit (PCTK) (OTHER), The Patient-SatisfActive® Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT02258594?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.